Compare XPON & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPON | CANF |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.2M |
| IPO Year | 2022 | 2011 |
| Metric | XPON | CANF |
|---|---|---|
| Price | $0.53 | $3.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 136.9K | ★ 942.3K |
| Earning Date | 05-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,651,870.00 | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 71.59 | N/A |
| 52 Week Low | $0.49 | $0.17 |
| 52 Week High | $5.50 | $10.40 |
| Indicator | XPON | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 27.73 | 52.09 |
| Support Level | $0.49 | $2.89 |
| Resistance Level | $0.84 | $4.74 |
| Average True Range (ATR) | 0.05 | 0.30 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 13.07 | 49.57 |
Expion360 Inc focuses on the design, assembly, manufacturing, and sale of lithium iron phosphate (LiFePO4) batteries and related accessories for RV, marine, and industrial applications. Its high-performance battery solutions are designed for high energy density and a compact footprint, supported by engineering and intellectual property to enhance safety, quality, and performance. The company also engages in product design, development, and collaboration to strengthen customer relationships. It serves dealers, wholesalers, private-label customers, and OEMs, who distribute its products to end consumers. Its segment is Energy Storage (ES), providing lithium-based energy solutions backed by durable materials, optimized internal structures, and responsive customer service.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.